Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Antipyretics

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44 result(s) found for: Antipyretics. Displaying page 3 of 3.
    « Previous 1  2  3 
    EudraCT Number: 2011-002035-26 Sponsor Protocol Number: 115411 Start Date*: 2011-10-21
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIIb observer-blind, randomized, multicentre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine and Merck's Quadrivalent ...
    Medical condition: Cervarix is indicated in females from 10 years of age onwards for the prevention of persistent infection, premalignant cervical lesions and cervical cancer (squamous-cell carcinoma and adenocarcino...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10033723 Papilloma viral infection NOS LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    14.0 10038604 - Reproductive system and breast disorders 10056576 Cervical intraepithelial neoplasia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: FR (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000930-37 Sponsor Protocol Number: M15-722 Start Date*: 2018-12-21
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Single-Arm, Open-Label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Prematurely Ended) ES (Completed) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005910-11 Sponsor Protocol Number: GWSP0604 Start Date*: 2007-08-29
    Sponsor Name:GW Pharma Ltd
    Full Title: A two-phase Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response asse...
    Medical condition: Spacticity in multiple sclerosis (MS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003230-42 Sponsor Protocol Number: F13640GE210 Start Date*: 2007-10-08
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Study of the analgesic effects of repeated doses of F13640 in spinal cord injury patients with moderate to severe central neuropathic pain. A multinational, multicenter, randomized, double blind, p...
    Medical condition: Central neuropathic pain due to spinal cord injury, based on clinical history, clinical examination and appropriate assessment of patient’s signs and symptoms, according to the International Associ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064012 Central pain syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) FI (Prematurely Ended) ES (Completed) BE (Completed) IT (Prematurely Ended) NL (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 13:40:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA